Characteristics of complete responders
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Diagnosis | AML after MF | AML after MF | AML after ET |
| Cytogenetics | Diploid | Diploid | der(1;7) (q10;p10) |
| Prior therapy | Decitabine | Lenalidomide + prednisone | AZD |
| Sunitinib | Cytarabine + clofarabine | ||
| Decitabine | |||
| Response | CR | CR | CRi |
| Pre-/post- % BM blast | 12*/1 | 48/1 | 14*/5 |
| Pre-/postplatelet count, ×103/μL | 54/163 | 129/280 | 302/116 |
| Pre-/post- % JAK2 mutation allele burden | 15/24 | −/− | 67/73 |
| Other responses | Reduced spleen size | Reduced spleen size | Reduced spleen size |
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Diagnosis | AML after MF | AML after MF | AML after ET |
| Cytogenetics | Diploid | Diploid | der(1;7) (q10;p10) |
| Prior therapy | Decitabine | Lenalidomide + prednisone | AZD |
| Sunitinib | Cytarabine + clofarabine | ||
| Decitabine | |||
| Response | CR | CR | CRi |
| Pre-/post- % BM blast | 12*/1 | 48/1 | 14*/5 |
| Pre-/postplatelet count, ×103/μL | 54/163 | 129/280 | 302/116 |
| Pre-/post- % JAK2 mutation allele burden | 15/24 | −/− | 67/73 |
| Other responses | Reduced spleen size | Reduced spleen size | Reduced spleen size |
AML indicates acute myeloid leukemia; MF, myelofibrosis; ET, essential thrombocythemia; CR, complete response; CRi, CR with insufficient recovery of blood count; and AZD, AZD1480 (an investigational JAK2 inhibitor).
These patients with AML had received prior therapy, had recovered from their effects, and had not achieved CR with persistent disease although < 20% blasts.